The application for the listing of the new crown vaccine for Coxing Zhongwei Bio-Crown was accepted by NMPA

recently, the industry came to the news that the new coronavirus inactivated vaccine (Kelleford) developed by Coxing Zhongwei Bio has been accepted by China's State Drug Administration (NMPA). The article said that the new corona vaccine in the overseas phase 3 clinical trials, the vaccine after good safety, 14 days after the completion of two doses of vaccination, the protection of diseases caused by the new coronavirus infection (COVID-19) to meet the relevant technical standards of the World Health Organization and China's State Drug Administration issued the "new coronavirus vaccine clinical evaluation guidelines (trial)" in the relevant standards. On February 3, Coxing Zhongwei Bio has officially submitted a conditional listing application to the State Drug Administration, and has been accepted.Prior to that, the vaccine had been approved for emergency use in Turkey, Brazil and Chile, Xinhua reported.On January 20, the Chilean Institute of Public Health also announced that it had granted emergency approval to Kelleford, a new crown vaccine developed by Kexing Holdings Beijing Coxing Zhongwei Biotechnology Co., Ltd. It is reported that the Acting President of the Chilean Institute of Public Health Garcia said after the vote of the committee of experts that the new crown vaccine developed by Coxing Zhongwei is a safe and effective vaccine, can effectively reduce the rate of severe infection and hospitalization, so decided to give it emergency use permits. Chile is currently working with COSCO on its Phase 3 clinical studies.On January 17th, a new coronavirus inactivated vaccine (trade name: Krlef), developed by Cochlear Zhongwei Bio, was granted emergency use permits in Brazil. According to the clinical results of phase 3 published by the state government of Sao Paulo, Brazil, on the 12th, the vaccine is 100% effective in protecting patients with new coronary severe illnesses and inpatients, 77.96 percent in the protection of minor cases in need of medical treatment, and 50.4 percent in overall protection. Some experts pointed out that the protection rate of 100% of severe cases, meaning that the vaccine can greatly reduce the risk of serious illness, the overall protection effect of 50.4%, meaning that the vaccine can reduce the risk of contracting neo-crown pneumonia by more than 50%.On January 13th Turkey's Medicines and Medical Devices Agency announced that it had approved the emergency use of the new crown vaccine, Klef, becoming the first new crown vaccine approved for use in Turkey. It is reported that in September 2020, the new crown vaccine developed by Koxing Zhongwei Bio began to carry out Phase 3 clinical trials in Turkey. According to preliminary analysis data released by the Turkish Ministry of Health on 24 December 2020, the vaccine is 91.25% effective and no serious side effects were detected during clinical trials. (Drug Ming Kant)